-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On December 15th, Nuvation announced that the US FDA has granted the company's CDK2/4/6 inhibitor NUV-422 fast track designation for the treatment of high-grade gliomas, including glioblastoma multiforme
CDK4/6 inhibitors have been shown to be effective against malignant tumors, but some cancer cells can evade cdk4/6 treatment by increasing the CDK2 signaling pathway
Pre-clinical studies have shown that NUV-422 has good blood-brain barrier penetration
Preclinical data shows that in the in vivo xenograft model of glioblastoma multiforme, NUV-422 has a better tumor suppressor effect than standard care therapy temozolomide
In addition to high-grade glioma, NUV-422 is currently being developed to treat HR+/HER2-advanced breast cancer (with or without brain metastasis) and metastatic castration-resistant prostate cancer (mCRPC)
The Phase I/II study of NUV-422 for the treatment of adult relapsed or refractory high-grade gliomas and solid tumors is ongoing